All In Biotech

Drug Trial Radar · NCT06350032

Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH

Open-label, Single-arm, Non-controlled Trial to Evaluate Safety and Tolerability of Treprostinil Sodium in Children Below the Age of 18 Years Diagnosed With Pulmonary Arterial Hypertension (PAH)

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jul 31, 2024

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
AOP Orphan Pharmaceuticals AGIndustry
Sponsor type
Industry
First posted
Apr 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate safety and tolerability of preservative-free parenteral treprostinil in paediatric patients with PAH (PH Group 1) who are below 18 years of age. The main question it aims to answer is: • if preservative-free parenteral treprostinil is safe and tolerable in the treatment of paediatric PAH in patients who are either prostacyclin-naïve or have been previously treated with commercially available parenteral treprostinil formulations. Participants will receive either subcutaneous (SC) or intravenous (IV) preservative-free treprostinil and will be observed for 5 months (20 weeks ± 1 week).

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • preservative-free parenteral treprostinilDrug

    Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and seriousness of adverse events and adverse drug reactionsTime frame: 5 months (20 weeks ± 1 weeks)

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • Medizinische Universität Wien

    Vienna, State of Vienna, Austria · Recruiting

  • Necker-Enfants Malades Hospital, Paris

    Paris, Paris, France · Recruiting

  • Gottsegen National Cardiovascular Center

    Budapest, Budapest, Hungary · Recruiting

  • Pediatric Cardiac Center

    Bratislava, Slovakia · Recruiting

  • Ramón y Cajal University Hospital

    Madrid, Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.